Advertisement
UK markets open in 1 hour 55 minutes
  • NIKKEI 225

    39,108.40
    +491.30 (+1.27%)
     
  • HANG SENG

    18,930.02
    -265.58 (-1.38%)
     
  • CRUDE OIL

    77.01
    -0.56 (-0.72%)
     
  • GOLD FUTURES

    2,374.60
    -18.30 (-0.76%)
     
  • DOW

    39,671.04
    -201.95 (-0.51%)
     
  • Bitcoin GBP

    54,632.50
    -57.97 (-0.11%)
     
  • CMC Crypto 200

    1,513.77
    -12.65 (-0.83%)
     
  • NASDAQ Composite

    16,801.54
    -31.08 (-0.18%)
     
  • UK FTSE All Share

    4,560.55
    -23.85 (-0.52%)
     

GSK, Prosensa muscular dystrophy drug misses study goal

LONDON, Sept 20 (Reuters) - An experimental drug for Duchenne muscular dystrophy from GlaxoSmithKline (Other OTC: GLAXF - news) and Prosensa failed to meet its goal in a late-stage clinical trial, the companies said on Friday.

The drug, drisapersen, did not show a statistically significant improvement in the distance that patients could walk in six minutes compared to placebo in the Phase III test.